Clinical Trials Browser

Phase 2 × Capecitabine × Head & Neck × Clear all

NCT07303283 2026-03-05

Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma

Phase 2 Not yet recruiting

Nasopharyngeal Carcinoma

NCT05126719 2026-02-06

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma

Phase 2 Active not recruiting

Nasopharyngeal Carcinoma, Recurrence

NCT05807880 2026-01-23

ALTER-HN005

Phase 2 Active not recruiting

Nasopharyngeal Neoplasms

NCT07331428 2026-01-09

MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPC

Phase 2 Not yet recruiting

Nasopharyngeal Carcinoma

NCT04428151 2025-12-04

LEAP-009

Phase 2 Completed

408 enrolled 17 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck

NCT07254962 2025-11-28

CAPTURE

Phase 2 Not yet recruiting

Head and Neck Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms

NCT05007106 2025-08-14

KEYVIBE-005

Phase 2 Completed

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT06494995 2025-06-04

AK104 and Low-dose Radiation in Recurrent/Metastatic HNSCC After Failure of First-line Systemic Therapy

Phase 2 Recruiting

Diabetes Mellitus, Insulin-Dependent, 12, Squamous Cell Carcinoma of Head and Neck

NCT06987123 2025-05-23

TC as Adjuvant Therapy After Surgery for Locally Recurrent Resectable Nasopharyngeal Carcinoma: a Single-arm Clinical Trial

Phase 2 Not yet recruiting

Nasopharyngeal Carcinoma

NCT04517214 2025-04-02

Comparing Chemotherapy With/Without Toripalimab For Primary Metastatic Nasopharyngeal Carcinoma

Phase 2 Active not recruiting

Nasopharyngeal Carcinoma

NCT06892431 2025-03-25

JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer

Phase 2 Not yet recruiting

Nasopharyngeal Neoplasms, Recurrence

NCT06259721 2024-03-07

Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma

Phase 2 Recruiting

Nasopharyngeal Carcinoma

NCT04156698 2023-08-09

Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma

Phase 2 Unknown

Hypopharyngeal Neoplasms

NCT05965154 2023-07-28

Calizumab Combined With Bevacizumab and Capecitabine in the Treatment of Head and Neck Squamous Cell Carcinoma

Phase 2 Unknown

Squamous Cell Carcinoma of Head and Neck

NCT04072107 2023-06-18

EP-STAR

Phase 2 Unknown

Nasopharyngeal Carcinoma

NCT05549466 2023-02-08

Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPC

Phase 2 Unknown

Nasopharyngeal Carcinoma

NCT05514275 2022-08-24

Radiotherapy Combined With Endostatin and Capecitabine for NPC

Phase 2 Recruiting

Nasopharyngeal Carcinoma

NCT05484375 2022-08-02

Capecitabine Plus Toripalimab Maintenance Therapy in Metastatic Nasopharyngeal Carcinoma After First-line Treatment

Phase 2 Not yet recruiting

Nasopharyngeal Carcinoma

NCT05201859 2022-05-06

Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal Carcinoma

Phase 2 Unknown

Nasopharyngeal Carcinoma

NCT05290194 2022-04-14

Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine in the Treatment of Nasopharyngeal Carcinoma

Phase 2 Recruiting

Nasopharyngeal Carcinoma

NCT00124527 2021-06-16

Study of Irofulven Plus Capecitabine in Patients With Advanced Thyroid Cancer

Phase 2 Completed

Thyroid Neoplasms

NCT00266279 2020-09-03

Phase II (Treatment) Study of Oxaliplatin and Capecitabine in Advanced Head and Neck Malignancies

Phase 2 Completed

17 enrolled 6 charts

Head and Neck Neoplasms

NCT04220528 2020-01-07

Radical Radiotherapy and Chemotherapy Combined With Maintenance Chemotherapy in the Treatment of Stage N3 NPC

Phase 2 Unknown

Nasopharyngeal Carcinoma

NCT03678649 2018-09-19

A Prospective Randomized Trial of Capecitabine Treatment in Patients With HNSCC

Phase 2 Unknown

Head and Neck Neoplasms

NCT00095901 2018-03-29

Capecitabine For Nasopharyngeal Cancer

Phase 2 Completed

Head and Neck Neoplasms

NCT03427359 2018-02-09

Induction Cisplatin and Capecitabine Followed by Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma

Phase 2 Completed

Nasopharyngeal Carcinoma

NCT01267240 2017-04-14

Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer

Phase 2 Terminated

25 enrolled 9 charts

Squamous Cell Carcinoma of Head and Neck

NCT00101075 2017-02-27

Title XELOX FOR SALIVARY GLAND CANCERS

Phase 2 Terminated

Head and Neck Neoplasms, Salivary Gland Neoplasms

NCT00448552 2016-12-15

Oxaliplatin and Capecitabine in Treating Patients With Relapsed or Metastatic Head and Neck Cancer

Phase 2 Completed

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Salivary Gland Neoplasms, Esthesioneuroblastoma, Olfactory

NCT00439426 2016-11-02

A Study of Xeloda (Capecitabine) in Combination With XELOX (Oxaliplatin) in Patients With Metastatic Nasopharyngeal Cancer.

Phase 2 Completed

Nasopharyngeal Neoplasms

NCT02360501 2016-04-20

Combination of Docetaxel, Cisplatin, and Capecitabine (DCX) in the Treatment of Nasopharyngeal Carcinoma

Phase 2 Completed

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

NCT00095641 2013-11-08

S0225 Capecitabine in Treating Patients Who Have Undergone Surgery for Locally Recurrent or Persistent Head and Neck Cancer

Phase 2 Withdrawn

Squamous Cell Carcinoma of Head and Neck